• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

Pyrido[2,3-b]pyrazine, 7-bromo-1,2,3,4-tetrahydro-4-methyl- (CAS No. 1211581-98-4): A Comprehensive Overview

The compound Pyrido[2,3-b]pyrazine, 7-bromo-1,2,3,4-tetrahydro-4-methyl-, identified by its CAS number CAS No. 1211581-98-4, is a heterocyclic organic molecule that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the pyrido[2,3-b]pyrazine scaffold, a class of nitrogen-containing heterocycles that are known for their diverse biological activities and potential therapeutic applications.

Pyrido[2,3-b]pyrazines are a structurally intriguing class of compounds characterized by a fused bicyclic system consisting of a pyridine ring and a pyrazine ring. The presence of multiple nitrogen atoms in this scaffold makes it highly versatile for interactions with biological targets. In particular, the brominated derivative 7-bromo-1,2,3,4-tetrahydro-4-methyl-pyrido[2,3-b]pyrazine has been extensively studied due to its unique structural features and potential pharmacological properties.

The< strong>7-bromo substituent at the 7-position of the pyrido[2,3-b]pyrazine core is particularly significant as it introduces a halogen atom that can participate in various chemical reactions and biological interactions. This bromine atom can serve as a handle for further functionalization, enabling the synthesis of more complex derivatives with tailored biological activities. Additionally, the< strong>1,2,3,4-tetrahydro moiety and the< strong>4-methyl group contribute to the overall steric and electronic properties of the molecule, influencing its binding affinity and selectivity towards biological targets.

In recent years, there has been growing interest in exploring the pharmacological potential of pyrido[2,3-b]pyrazine derivatives. These compounds have shown promise in various preclinical studies as scaffolds for developing drugs targeting a wide range of diseases. Notably, some derivatives have demonstrated antitumor activity by inhibiting key signaling pathways involved in cancer cell proliferation and survival.

The< strong>7-bromo-1,2,3,4-tetrahydro-4-methyl-pyrido[2,3-b]pyrazine has been investigated for its potential role in modulating enzymes and receptors that are implicated in inflammatory and neurological disorders. Preliminary studies suggest that this compound may interact with specific proteins involved in these pathways, leading to therapeutic effects. For instance, it has been hypothesized that this molecule could interfere with the activity of enzymes such as tyrosine kinases or other signaling molecules that are dysregulated in certain pathological conditions.

The synthesis of< strong>Pyrido[2,3-b]pyrazine derivatives is typically achieved through multi-step organic reactions that involve cyclization and functional group transformations. The introduction of the< strong>7-bromo,< strong>1,2,3,4-tetrahydro, and< strong>4-methyl substituents requires careful optimization of reaction conditions to ensure high yield and purity. Advanced synthetic techniques such as transition metal-catalyzed cross-coupling reactions have been employed to facilitate the introduction of these functional groups efficiently.

The pharmacological evaluation of< strong>CAS No. 1211581-98-4 involves both in vitro and in vivo studies to assess its biological activity and safety profile. In vitro assays are conducted to determine the compound's interaction with specific target proteins or enzymes using techniques such as enzyme inhibition assays or receptor binding studies. These studies provide valuable insights into the mechanism of action and potential therapeutic relevance of the compound.

In vivo studies are essential for evaluating the efficacy and toxicity of< strong>CAS No. 1211581-98-4. Animal models are used to assess the compound's pharmacokinetic properties, such as absorption distribution metabolism excretion (ADME), as well as its therapeutic effects on disease models relevant to its intended application. These studies help to validate the preclinical findings and provide a basis for further development efforts.

The structural features of< strong(Pyrido[2,b]pyrazine derivatives make them attractive candidates for drug discovery due to their ability to modulate biological pathways involved in various diseases. The< strong>7-bromo,< strong>tetrahydro, and< strong>methyl substituents contribute to the compound's unique pharmacological profile by influencing its binding affinity and selectivity towards biological targets. This makes it a valuable scaffold for developing novel therapeutic agents.

The future directions for research on< strong>CAS No. 1211581-98-4 include further exploration of its pharmacological potential in different disease models and optimization of its chemical structure for improved efficacy and safety. Additionally,< strong>sustainable synthetic methodologies should be developed to ensure efficient production at scale while minimizing environmental impact.

In conclusion,< strong(Pyrido[2,b]pyrazine derivatives represent a promising class of compounds with significant therapeutic potential. The specific derivative known asCAS No. 1211581-98-4, particularly characterized by its) exhibits unique structural features that make it an attractive candidate for drug development. Ongoing research efforts aim to fully elucidate its biological activities and explore its potential as a therapeutic agent for various diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)